Arax Advisory Partners
FENC icon

Arax Advisory Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Arax Advisory Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.02K Buy
+653
New +$5.33K ﹤0.01% 4487
2025
Q4 		– Sell
-188
Closed -$1.76K – 4233
2025
Q3 		$1.76K Buy
+188
New +$1.63K ﹤0.01% 3143

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Arax Advisory Partners's FENC Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Fennec Pharmaceuticals (FENC) in Q2 2026: 653 shares worth $7.02K. The stake represents ﹤0.01% of the portfolio and ranks #4487 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in FENC as recently as Q3 2025.

Arax Advisory Partners first reported a position in FENC in Q3 2025 and has held it in 2 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Arax Advisory Partners held 653 shares of Fennec Pharmaceuticals worth $7.02K as of Q2 2026.
  • Fennec Pharmaceuticals was a new Arax Advisory Partners position in Q2 2026.
  • Fennec Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4487 holding.
  • Arax Advisory Partners first reported a position in Fennec Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.